PURPOSE: The aims of this study were to determine the proportion of return to work (RTW) among sick-listed patients diagnosed with one of eight subtypes of hematological malignancies; to evaluate the influence of type of hematological malignancy, comorbidity, use of anxiolytics and antidepressants, socioeconomic and demographic factors on RTW; and to investigate if these associations differ between genders. METHODS: We combined data from national registers on all Danish patients diagnosed with hematological malignancies between 2000 and 2007. A total of 1,741 patients on long-term sick leave were followed until RTW, emigration, permanent withdrawal from the labor market, death, or February 2012, whichever came first. RESULTS: A total of 1,140 (65 %) patients returned to work. A strong association was found between type of diagnosis and RTW (p < 0.001), and the proportion of RTW was lowest for patients with multiple myeloma or acute leukemia compared to patients with Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, chronic myeloid leukemia, and chronic lymphoid leukemia. Use of antidepressants or anxiolytics after diagnosis, gender, age, and educational level were also associated with RTW. Surprisingly, comorbidity was not associated with RTW (p = 0.94); gender only modified the association between age and RTW. CONCLUSION: Two thirds of patients with hematological malignancies on sick leave RTW. A number of factors seem to lead to a poor prognosis, the hematological diagnosis being the most important, and these should be taken into account when performing studies on work outcome for patients with hematological malignancies. IMPLICATIONS FOR CANCER SURVIVORS: Knowledge in this area should assist in identification of hematological cancer patients at risk of not returning to work so that early targeted rehabilitation interventions can be initiated.
PURPOSE: The aims of this study were to determine the proportion of return to work (RTW) among sick-listed patients diagnosed with one of eight subtypes of hematological malignancies; to evaluate the influence of type of hematological malignancy, comorbidity, use of anxiolytics and antidepressants, socioeconomic and demographic factors on RTW; and to investigate if these associations differ between genders. METHODS: We combined data from national registers on all Danish patients diagnosed with hematological malignancies between 2000 and 2007. A total of 1,741 patients on long-term sick leave were followed until RTW, emigration, permanent withdrawal from the labor market, death, or February 2012, whichever came first. RESULTS: A total of 1,140 (65 %) patients returned to work. A strong association was found between type of diagnosis and RTW (p < 0.001), and the proportion of RTW was lowest for patients with multiple myeloma or acute leukemia compared to patients with Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, chronic myeloid leukemia, and chronic lymphoid leukemia. Use of antidepressants or anxiolytics after diagnosis, gender, age, and educational level were also associated with RTW. Surprisingly, comorbidity was not associated with RTW (p = 0.94); gender only modified the association between age and RTW. CONCLUSION: Two thirds of patients with hematological malignancies on sick leave RTW. A number of factors seem to lead to a poor prognosis, the hematological diagnosis being the most important, and these should be taken into account when performing studies on work outcome for patients with hematological malignancies. IMPLICATIONS FOR CANCER SURVIVORS: Knowledge in this area should assist in identification of hematological cancerpatients at risk of not returning to work so that early targeted rehabilitation interventions can be initiated.
Authors: Corné A Roelen; Petra C Koopmans; Johan W Groothoff; Jac J van der Klink; Ute Bültmann Journal: Psychooncology Date: 2010-07-28 Impact factor: 3.894
Authors: Michael Feuerstein; Briana L Todd; Michal C Moskowitz; Gina L Bruns; Mallori R Stoler; Thomas Nassif; Xinhua Yu Journal: J Cancer Surviv Date: 2010-10-14 Impact factor: 4.442
Authors: Karen L Syrjala; Shelby L Langer; Janet R Abrams; Barry Storer; Jean E Sanders; Mary E D Flowers; Paul J Martin Journal: JAMA Date: 2004-05-19 Impact factor: 56.272
Authors: I Glimelius; S Ekberg; J Linderoth; M Jerkeman; E T Chang; M Neovius; K E Smedby Journal: J Cancer Surviv Date: 2015-02-18 Impact factor: 4.442
Authors: S J Tamminga; U Bültmann; O Husson; J L P Kuijpens; M H W Frings-Dresen; A G E M de Boer Journal: Qual Life Res Date: 2015-09-22 Impact factor: 4.147
Authors: Graham Jackson; Jayne Galinsky; David E C Alderson; Vijay K D'Souza; Vanessa Buchanan; Sujith Dhanasiri; Simon Walker Journal: Eur J Haematol Date: 2019-08-12 Impact factor: 2.997
Authors: Christine Bennink; Marjolein van der Klift; Hans Scheurer; Pieter Sonneveld; Saskia F A Duijts Journal: Eur J Cancer Care (Engl) Date: 2021-06-21 Impact factor: 2.328